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Abstract Programmed death 1 (PD-1) is a co-inhibitory
receptor in the CD28/CTL-4 family, and functions as a
negative regulator of the immune system. Tumor-infiltrat-
ing lymphocytes (TIL) in many epithelial cancers express
PD-1, suggesting that antitumor immunity may be modu-
lated by the PD-1/PD-L1 signaling pathway, and promising
results from two recent clinical trials with monoclonal
antibodies targeting PD-1 or PD-L1 confirm the clinical
relevance of this pathway in human cancer. To explore the
role of PD-1? TIL in human breast cancer, we performed
immunohistochemistry studies on a tissue microarray
encompassing 660 breast cancer cases with detailed clini-
cal annotation and outcomes data. PD-1? TIL were present
in 104 (15.8 %) of the 660 breast cancer cases. Their
presence was associated with tumor size, grade, and lymph
node status, and was differentially associated with the
intrinsic subtypes of breast cancer. In univariate survival
analyses, the presence of PD-1? TIL was associated with a
significantly worse overall survival (HR = 2.736,
p \ 0.001). In subset analyses, the presence of PD-1? TIL
was associated with significantly worse overall survival in
the luminal B HER2- subtype (HR = 2.678, p \ 0.001),
the luminal B HER2? subtype (HR = 3.689, p \ 0.001),
and the basal-like subtype (HR = 3.140, p \ 0.001). This
is the first study to demonstrate that the presence of PD-1?
TIL is associated with poor prognosis in human breast
cancer, with important implications for the potential
application of antibody therapies targeting the PD-1/PD-L1
signaling pathway in this disease.
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Introduction
Upon antigen recognition, T cells integrate signals from the
T cell receptor, and costimulatory receptors of the CD28/
CTLA-4 family [1]. Signaling from costimulatory receptors
can be either activating or inhibitory, and the balance
between costimulatory and co-inhibitory signals regulates
T cell activation and tolerance [1]. Programmed death-1
(PD-1) is a member of the CD28/CTLA-4 family of
costimulatory receptors, and, together with Cytotoxic
T-Lymphocyte Antigen 4 (CTLA-4) [2] and B and T lym-
phocyte attenuator (BTLA) [3], conveys an inhibitory signal
to the T cell. PD-1 is constitutively expressed on a subset of
thymic T-lymphocytes, and is upregulated on activated
T-cells, B-cells, and myeloid cells [4, 5]. PD-1 is particularly
important in peripheral tolerance to self-antigens [6]. PD-1
signaling leads to cell cycle arrest in G0/G1 but does not
increase cell death [4]. Persistent high-level PD-1 expression
on antigen-experienced CD8? T cells is associated with a
CD8? T cell phenotype defined by impaired effector
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function and the persistent expression of inhibitory receptors
[7], termed ‘‘T cell exhaustion’’.
Recent studies have underscored the significance of
PD-1 in human disease. PD-1 is significantly upregulated
on HIV-specific T cells in patients with chronic infection.
Its expression is associated with impaired T cell function,
and with predictors of disease progression including
plasma viral load [8] and CD4? T cell count [9–12].
In vitro blockade of PD-1 significantly enhances HIV-
specific T cell function, clearly defining a reversible
immunoregulatory pathway. In addition, there is increasing
evidence that it is equally important in human cancer. PD-1
is significantly upregulated on cancer-specific T cells
[13–17], and the PD-1 ligand, PD-L1, is expressed by a
variety of epithelial cancers [18–20], suggesting that these
malignancies may use the PD-1/PD-L1 signaling pathway
to attenuate or escape antitumor immunity by maintaining
an immunosuppressive tumor microenvironment. Support-
ing this hypothesis is the fact that despite the induction of
cancer-specific T cells in many trials of adoptive cell
therapy, with concomitant infiltration of tumor sites, tumor
growth is seldom controlled [21].
Based on these findings, targeting the PD-1 pathway to
enhance antitumor immunity is under investigation in
multiple human cancers [22–24]. Two recently reported
phase I clinical trials investigated the effects of fully
human anti-PD-1 and anti-PD-L1 antibodies in patients
with various types of advanced solid cancers [25, 26]. The
antibodies were administered intravenously in patients with
melanoma, renal cell carcinoma, and non-small-cell lung
cancer, and both studies showed objective responses
(response rates 6–28 %). Of note, success was documented
in cancers that have long been considered to be resistant to
immunotherapy, such as non-small-cell lung cancer. In
addition, some of these responses were durable, suggesting
that targeting the PD-1/PD-L1 signaling pathway is likely
to develop into an important treatment modality for
patients with advanced malignancies. However, neither of
these two trials included a significant number of breast
cancer patients. In the anti-PD-1 antibody study by Topa-
lian et al., there were no breast cancer patients, and in the
anti-PD-L1 antibody study by Brahmer et al. [26], there
were only four breast cancer patients. Therefore, defining
the importance of the PD-1/PD-L1 signaling pathway in
breast cancer is of significant clinical relevance, with the
potential to provide significant insights into whether anti-
body therapies targeting this pathway will be appropriate in
breast cancer patients.
Although breast cancer is commonly thought to be less
immunogenic than melanoma or renal cell carcinoma, there
is increasing evidence of a dynamic crosstalk between the
immune system and breast cancer. Evidence of this
crosstalk includes the presence and clinical significance of
immune infiltrates in breast cancer [27, 28], the increased
prevalence of regulatory T cells [14, 29], as well as
reported upregulation of inhibitory molecules of the CD28
receptor family on breast cancer-specific T cells [13–15]
and of PD-L1 on breast cancer cells [15]. Ghebeh et al. [14]
analyzed 62 breast cancer specimens and found that PD-1
was expressed in up to 70 % of tumor-infiltrating lym-
phocytes (TIL) compared to 30 % in normal breast tissue,
and the presence of PD-1? TIL was associated with his-
tologic grade, estrogen receptor (ER), and progesterone
receptor (PR) status. In a similar study, the same authors
also found expression of PD-L1 on breast cancers cells as
well as on TIL in 50 % of cases (n = 44). Expression of
PD-L1 on either cancer cells or TIL was associated with
tumor size, histologic grade, ER status, PR status, and
human epidermal growth factor receptor 2 (HER2) status
[15]. This finding was supported by Brown et al. [18] who
showed that 9 out of 12 breast carcinomas expressed PD-
L1, while very low expression was found on adjacent
normal breast tissue. In addition, PD-L1 is also expressed
by a number of human breast cancer cell lines [4]. Taken
together, these results suggest that activation of the PD-1/
PD-L1 signaling pathway in the breast cancer microenvi-
ronment may modulate antitumor immunity, permitting
cancer progression.
BTLA, a recently identified co-inhibitory receptor of the
CD28 receptor family, also inhibits proliferation of T cells
and cytokine secretion [30]. Investigating the role of BTLA
in cancer, Wang et al. [31] showed BTLA to be upregulated
in pleural fluid T cells of patients with lung cancer. It has also
been shown that tumor antigen-specific effector CD8? T
cells in melanoma express high levels of BTLA [32], and that
simultaneous blockade of both PD-1 and BTLA enhances the
expansion, proliferation, and function of these cells [33].
These data suggest that similar to PD-1, BTLA also could
play a role in limiting cancer immunosurveillance.
So far, studies investigating the roles of PD-1 and PD-
L1 in human breast cancer have involved relatively small
series, and the role of BTLA in breast cancer has not been
analyzed. To further explore the prevalence and roles of
PD-1? and BTLA? TIL in human breast cancer, we con-
ducted immunohistochemistry studies using a breast cancer
tissue microarray (TMA) encompassing a total of 1460
formalin fixed breast cancer cases with detailed clinical
annotation and outcomes data. The aim of the present study
was to investigate the association between PD-1? TIL, and/
or BTLA? TIL, and clinicopathological parameters in
breast cancer, with a particular focus on any potential
association with prognosis. The data are reported according
to the reporting recommendations for tumor marker prog-
nostic studies (REMARK) [34].
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Materials and methods
Tissue microarray
We used a TMA encompassing 1460 breast cancer tissue
punches from formalin-fixed and paraffin-embedded tumor
samples collected from patients diagnosed with primary
breast cancer between 1985 and 2007 at the Institute for
Pathology, University of Basel and the Viollier Institute in
Basel, Switzerland. Of these 1460 tissue punches, a total of
660 were evaluable for our study. The tissue samples were
brought into a TMA format as previously described [35].
Briefly, 0.6 mm tissue cylinders were punched out of donor
tumor tissue blocks and transferred into a recipient paraffin
block using a semi-automated tissue arrayer. Histopatho-
logic data was obtained from the pathology reports, and
raw patient survival data was obtained from the Cancer
Registry of Basel or from the patient’s attending physician.
Retrieval of tissue and clinical data was performed
according to the regulations of the local institutional review
boards and data safety laws with specific regard to ethical
standards and patient confidentiality. The mean follow up
time was 65 months (range 1 to 174 months), and the mean
age of the patients at diagnosis was 64 years (range 27 to
101 years). Demographic information of the patients can
be found in Table 1.
Immunohistochemistry
For immunohistochemical staining, 4 lm sections of the
TMA blocks were incubated overnight with a prediluted
mouse antihuman PD-1 monoclonal antibody (Cell Mar-
que, Clone MRQ-22, Rocklin, CA, USA) or the mouse
antihuman BTLA monoclonal antibody (dilution 1:50,
Clone FLO67B, a kind gift from G. Roncador, Centro
Nacional de Investigaciones Oncologicas, Madrid, Spain)
after heat induced antigen retrieval with Citrate buffer at
pH 6 and TEA buffer at pH 8, respectively. Standard DAB-
technique (Dako EnVision? System-labeled polymer anti-
mouse followed by Liquid DAB? Substrate Chromogen
System) was employed for immunostaining. Counterstain-
ing was performed with hematoxylin solution. The number
of PD-1? and BTLA? TIL were counted in each breast
cancer tissue punch. Normal human lymph node tissue was
used as a positive control. The staining intensity of ER, PR,
and HER2 was scored as described previously [36].
Flow cytometry of human breast cancer specimens
Fresh human breast cancer specimens were cut into small
pieces (5 9 5 mm), and digested with collagenase B
(Roche Diagnostics, Mannheim, Germany) at 37 C for
15 min. The mixture was then put on the Gentlemacs
Dissociator (Miltenyi Biotec, Bergisch Gladbach, Ger-
many) for 30 s and filtered through a 70 lm filter. The
remaining cell suspension was washed and resuspended in
FACS staining buffer, at a concentration of 1 9 106 cells/
50 ll in 5 mL round-bottom polystyrene tubes. Subse-
quently antihuman CD16/CD32 Fc-block (BD Biosciences,
San Jose, CA, USA) was added to the staining cocktail and
incubated for 10 min at room temperature. For PD-1
staining, APC-conjugated mouse antihuman CD3 (BD
Pharmingen, Franklin Lakes, NJ, USA), PE-conjugated
mouse antihuman CD4 (BD Pharmingen), Alexa-Fluor
488-conjugated mouse antihuman CD8 (BioLegend, San
Table 1 Basic demographic data for 660 evaluable breast cancer
cases
Mean tumor size (mm) ± standard deviation
(SD)
33.6 ± 16.8
Mean age at diagnosis (years) ± standard
deviation (SD)
64.8 ± 14.3
Number
(n)
Percent
(%)
Tumor stage
pT1 184 27.9
pT2 357 54.1
pT3 35 5.3
pT4 84 12.7
Lymph node involvement
pN0 360 54.6
pN1 231 35.1
pN2 68 10.3
Tumor grade
1 147 22.3
2 261 39.5
3 252 38.2
Histologic subtype
Invasive ductal 489 76.3
Invasive lobular 75 11.7
Mucinous 23 3.6
Apocrine 3 0.5
Cribriform 14 2.2
Papillary 8 1.2
Medullary 29 4.5
Intrinsic subtype
Luminal A
(ER? and/or PR?, HER2-, Ki-67 \ 14 %)
85 12.9
Luminal B (HER2-negative)
ER? and/or PR?, HER2-, Ki-67 C 14 %)
314 47.7
Luminal B (HER2-positive)
(ER? and/or PR?, HER2?)
75 11.4
HER2 type (ER- or PR-, HER2?) 56 8.5
Basal-like (ER-, PR-, HER2-) 128 19.5
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Diego, CA, USA), and PerCP/Cy5.5-conjugated mouse
antihuman PD-1 (BioLegend) were added and incubated
for 15 min at room temperature. For BTLA staining, APC-
conjugated mouse antihuman CD19 (BD Pharmingen), PE-
Cy7-conjugated mouse antihuman CD8 (eBioscience, San
Diego, CA, USA), PE-conjugated mouse antihuman CD4
(BD Pharmingen), and Alexa Fluor 488-conjugated mouse
antihuman CD272/BTLA (AbD Serotec, Raleigh, NC,
USA) were added and incubated for 15 min at room tem-
perature. Samples were then washed twice with FACS
buffer, resuspended in FACS buffer and analyzed by flow
cytometry on a FACScalibur flow cytometer (BD Biosci-
ences) or a LSR II flow cytometer (BD Biosciences). The
acquired data was analyzed with FlowJo software.
Statistical analysis
The distributions of patient and clinical characteristics
between tumors with PD-1? TIL and tumors without PD-
1? TIL were compared using Chi square test, Wilcoxon
rank sum test, or two-sample t test, deemed appropriate.
Overall survival (OS) was defined as the time from the first
operation to death due to any cause. Survivors were cen-
sored at the date of last contact. Survival curves by
occurrence of any PD-1? TIL were estimated using the
Kaplan–Meier product-limit method and compared by log-
rank test. Univariate Cox proportional hazard models were
fit to identify factors significantly related to OS. To assess
whether the occurrence of any PD-1? TIL was an inde-
pendent predictor of survival, a multivariate Cox model
was constructed to adjust other patient/clinical character-
istics that were significant in the univariate analyses. Two-
way interaction terms between PD-1? TIL and other fac-
tors in the multivariate Cox model were also assessed. All
analyses were two-sided and significance was set at a
p value of 0.05. Statistical analyses were performed using
SAS (SAS Institutes, Cary, NC) Fig. 1.
Results
PD-1? TIL were present in a total of 104 (15.8 %) of the
660 evaluable primary breast cancers. The mean number of
PD-1? TIL present in the 104 breast cancer cases was 6
(range 1 to 50 TIL). The presence of PD-1? TIL was
significantly associated with tumor size, AJCC primary
tumor staging system (TNM), tumor grade, and lymph
node status (Table 2). The presence of PD-1? TIL was
positively associated with Ki-67 expression (p = 0.0051)
and negatively associated with ER expression (p \ 0.0001)
and PR expression (p = 0.0004) (Table 2, and data not
shown). There was no significant association between the
presence of PD-1? TIL and HER2 expression (p = 0.0921,
Table 2). Of note, the prevalence of PD-1? TIL differed
significantly among the different intrinsic subtypes of
breast cancer, as defined by the St Gallen consensus con-
ference [37]. The breast cancer intrinsic subtypes were
originally defined by gene expression profiling [38, 39] but
can be approximated using immunohistochemistry for ER,
PR, Ki-67, and HER2 [37, 40]. These subtypes are known
to have differing epidemiological risk factors, prognosis,
and response to therapy [37]. The prevalence of PD-1? TIL
was the highest in the basal-like subtype (27.4 %) and the
lowest in the luminal A subtype (4.7 %, p \ 0.0001)
(Table 3).
In univariate survival analyses, breast cancer cases with
any PD-1? TIL present had a significantly worse OS
(HR = 2.736, p \ 0.0001, Table 4; Fig. 2). In subset anal-
yses by intrinsic subtype, the presence of PD-1? TIL was
associated with decreased OS in the luminal B HER2-
subtype (HR = 2.678, p \ 0.0001), the luminal B HER2?
subtype (HR = 3.689, p = 0.0009), and the basal-like sub-
type (HR = 3.140, p \ 0.0001) (Table 4; Fig. 2). In multi-
variate analysis, after adjusting for age, grade, tumor size,
lymph node status, and intrinsic subtype, the presence of PD-
1? TIL proved to be an independent negative prognostic
Fig. 1 Representative photographs of PD-1? TIL in a breast cancer tissue punch. a Tissue punch with PD-1? TIL. Magnification 209 b PD-1?
TIL infiltrating a case of invasive ductal carcinoma. Magnification 4009
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factor for OS (HR = 1.532, p = 0.0198) (Table 5). In this
multivariate analysis, we excluded the HER2 subtype for two
reasons: 1) the univariate analysis indicated that the effect of
PD-1? TIL may be different in this subtype (Table 4). 2) the
HER2 subtype consists of only 56 cases and may preclude a
reliable testing of interaction between PD1 and intrinsic
subtypes. When looking at all breast cancer cases, The
number of PD-1? TIL was associated with worse OS
(HR = 1.031, p = 0.0175, data not shown). However,
owing to the relatively low number of cases with PD-1? TIL
(n = 104), this association may not be representative.
BTLA? TIL were present in 15 of the 660 breast cancer
cases (2.3 %, range of BTLA? TIL 1–452). Owing to the
small number of breast cancer cases with BTLA? TIL, we
Table 2 Association between
PD-1 expression and
clinicopathological parameters
Clinicopathologic parameter PD-1? PD-1- p value
Mean tumor size (mm) ± SD 39.5 ± 23.1 27.8 ± 14.6 \0.0001
Mean age at diagnosis (years) ± SD 66.2 ± 14.1 63.4 ± 14.2 0.0619
Tumor stage (n) \0.0001
pT1 14 7.6 170 92.4
pT2 48 13.5 309 86.5
pT3 12 34.3 23 65.7
pT4 30 35.7 54 64.3
Lymph node involvement \0.0001
pN0 30 8.3 330 91.7
pN1 29 12.5 202 87.5
pN2 45 66.2 23 33.8
Tumor grade \0.0001
1 7 4.8 140 95.2
2 34 13.0 227 87.0
3 63 25.0 189 75.0
Estrogen receptor \0.0001
ER? 56 12.0 409 88.0
ER- 48 24.9 145 75.1
HER2 0.0921
HER2? 27 20.6 104 79.4
HER2- 77 14.6 450 85.4
Ki67 0.0051
Ki67? 95 17.9 437 82.1
Ki67- 9 7.5 111 92.5
Table 3 Association between
PD-1 expression and breast
cancer intrinsic subtype
Intrinsic subtype PD-1? PD-1- p value
(n) (%) (n) (%) \0.0001
Luminal A
(ER? and/or PR?, HER2-, Ki-67 \ 14 %)
4 4.7 81 95.3
Luminal B (HER2-negative)
ER? and/or PR?, HER2-, Ki-67 C 14 %)
38 12.1 276 87.9
Luminal B (HER2-positive)
(ER? and/or PR?, HER2?)
14 18.7 61 81.3
HER2 type (ER-, PR-, HER2?) 13 23.2 43 76.8
Basal-like (ER-, PR-, HER2-) 35 27.3 93 72.7
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did not perform statistical analyses to determine if there is
an association between BTLA? TIL and clinicopathologi-
cal parameters or prognosis. Of note, all cases that showed
BTLA? TIL also contained PD-1? TIL.
To investigate the phenotype of PD-1? TIL in more
detail, we performed flow cytometry of cells freshly iso-
lated from three human breast cancers of the invasive
ductal subtype. A mean of 3.9 % of all cells in the tumors
expressed PD-1. 89.1 % of the PD-1? cells were CD3?
lymphocytes, and 80.9 % of the PD-1?/CD3?cells were
CD4?, and 17.9 % were CD8?, suggesting that PD-1 is
primarily expressed on CD4? T cells in human breast
cancer. 6.3 % of all CD3? lymphocytes expressed PD-1
Table 4 Univariate analyses for all cases, and by intrinsic subtype,
for the effect of PD-1 expression on overall survival
PD-1 expression, all cases Hazard ratio
(95 % CI)
p value
PD-1? 2.736 (2.066–3.625) \0.0001
PD-1 expression, by
intrinsic subtype
Luminal A 2.474 (0.551–11.120) 0.2374
Luminal B (HER2-) 2.678 (1.703–4.212) \0.0001
Luminal B (HER2?) 3.689 (1.712–7.949) 0.0009
HER2 type 0.536 (0.181–1.588) 0.2607
Basal-like 3.140 (1.886–5.230) \0.0001
Fig. 2 a Kaplan–Meier
survival curve for overall
survival depending on the
presence of PD-1? TIL
(univariate analysis); b–f
Kaplan–Meier survival curves
for overall survival depending
on the presence of PD-1? TIL
for the indicated breast cancer
intrinsic subtypes
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(Table 6; Fig. 3). We performed similar flow cytometric
analyses to investigate the phenotype of BTLA? cells in
human breast cancer. Less than 1 % of all cells in the
tumor expressed BTLA, and BTLA expression could not
be detected on CD4? or CD8? T cells (data not shown).
Discussion
In this study, we investigated the significance of PD-1?
TIL in a large cohort of clinically annotated primary breast
cancer specimens. We observed that PD-1? TIL are present
in 15.8 % of primary breast cancers, and the presence of
PD-1? TIL is associated with tumor size, AJCC primary
tumor staging system (TNM), tumor grade, lymph node
status, and biomarker profile (ER, PR, and HER2 status). In
addition, the presence of PD-1? TIL is differentially
associated with the intrinsic subtypes of breast cancer. Of
particular note, our study is the first to show that the
presence of PD-1? TIL in breast cancer is associated with a
significantly worse OS.
Our findings confirm and extend the results of Ghebeh
et al., but there are important differences between ours and
theirs. Ghebeh et al. [14] found that PD-1? TIL are present in
60 % of primary breast cancers, a significantly higher
prevalence than what we observed. However, their study was
relatively small (n = 62), and the authors evaluated whole
tumor sections, which may increase the likelihood of finding
PD-1? TIL. They also used a different PD-1 monoclonal
antibody, which may have a distinct staining pattern. Despite
these differences, Ghebeh et al. also found a correlation
between the presence of PD-1? TIL and higher tumor grade
in their series [14], although the small size of their series and
lack of clinical outcome data precluded a survival analysis.
Flow cytometry analyses confirm that PD-1 is expressed
mainly by CD3? lymphocytes in human breast cancer. This
result, as well as the morphologic appearance of the PD-1?
cells in the breast cancer tissue specimens, confirms our
assumption that the PD-1? cells identified by immunohis-
tochemistry are indeed TIL, obviating the need for double
staining with PD-1 and a T cell marker. Of note, the flow
cytometry analyses also demonstrate that the majority of
PD-1? cells are CD4? T cells, a finding that is surprising
considering that most of the studies so far have reported
that PD-1? TIL are predominantly CD8?, and it is believed
that suppression of CD8?/PD-1? tumor-specific T cells
may be a primary mechanism by which cancers evade
immune responses [7, 14, 16, 17]. However, a recent study
found that PD-1 is expressed on 73.4 % of CD4? TIL in
gastric cancer tissue and that these cells had impaired
function [41]. Similarly, PD-1 expression was found on up
to 76.4 % of CD4? T cells in Hodgkin’s lymphoma
specimens [42] and their presence is associated with
reduced overall survival [43]. In HPV-positive head and
neck cancer, PD-1 expression is also higher in CD4?T cells
than in CD8? T cells [44], and studies conducted in mel-
anoma patients show that PD-1 is upregulated on both
CD4? as well as CD8? TIL [17, 45].
Two recent phase I clinical trials have targeted the PD-
1/PD-L1 signaling pathway using fully human monoclonal
antibodies. These studies were associated with objective
clinical responses in cancers that have previously been
refractory to immunotherapy. Of note, Topalian et al. [25]
were able to assess PD-L1 expression in a subset of can-
cers, and preliminary results suggest that PD-L1 expression
by the cancer is associated with improved outcome fol-
lowing anti-PD-1 antibody therapy, suggesting that PD-L1
is a candidate biomarker for anti-PD-1 immunotherapy.
The data from this study, particularly the association
Table 5 Multivariate analysis for the effect of clinicopathologic
parameters and PD1 expression on overall survival
Clinicopathologic parameter Hazard ratio (95 % CI) p value
Age (per 1-year) 1.038 (1.027–1050) \0.0001
Tumor stage
pT1 (reference) 1
pT2 1.559 (1.036–2.347) 0.0334
pT3 2.157 (1.120–4.154) 0.0216
pT4 2.588 (1.572–4.261) 0.0002
Lymph node involvement
pN1 (reference) 1
pN1 1.310 (0.955–1.798) 0.0940
pN2 2.315 (1.499–3.576) 0.0002
Tumor grade
BRE grade 1 (reference) 1
2 1.751 (1.119–2.740) 0.0142
3 2.435 (1.535–3.863) 0.0002
Intrinsic subtypes
Luminal A 1
Luminal B (HER2-) 1.558 (0.877–2.770) 0.1306
Luminal B (HER2?) 1.838 (0.951–3.551) 0.0702
Basal-like 2.761 (1.482–5.143) 0.0014
PD-1 expression, all cases
PD-1? 1.532 (1.070–2.194) 0.0198
Table 6 Flow cytometry results for 3 breast cancer specimens
PD-1?
cells
PD-1? CD3?
cells
PD-1? CD4?
cells
PD-1? CD8?
cells
Patient 1 2.52 % 97.2 % 88.8 % 10.9 %
Patient 2 4.32 % 92.6 % 79 % 19.9 %
Patient 3 4.79 % 77.6 % 75.1 % 23 %
Breast Cancer Res Treat (2013) 139:667–676 673
123
between the presence of PD-1? TIL and higher stage, grade
and worse survival, suggest that PD-1 may also be a can-
didate biomarker for predicting response to therapy. PD-1
has two physiologic ligands, PD-L1 and PD-L2; assessing
PD-L1 expression may underestimate the number of
tumors that modulate the PD-1/PD-L1 signaling pathway.
However, if PD-1? TIL are present in the cancer, it sug-
gests that tumor-specific T cells have been primed but were
subsequently functionally inactivated. Reactivation of
these cells through PD-1/PD-L1 checkpoint blockade may
lead to enhanced antitumor immunity and improved clini-
cal outcome [25, 26, 46, 47].
It is important to note that the presence of PD-1? TIL is
differentially associated with the intrinsic subtypes of
breast cancer. The prevalence of PD-1? TIL is the highest
in the basal-like subtype and the lowest in the luminal A
subtype. In subset analyses, the presence of PD-1? TIL
proved to be a negative prognostic factor for OS in the
luminal B HER2- type, the luminal B HER2? type, and the
basal-like subtype. The increased prevalence of PD-1?
TIL, and strong association with survival in the basal-like
subtype are particularly relevant, as treatment options are
limited in this subtype, and PD-1-targeted therapies may
represent an attractive alternative or additive therapy in
this subset of breast cancer patients.
We also evaluated BTLA expression, a second co-
inhibitory receptor of the CD28/CTLA-4 family. However,
we found very few breast cancers with BTLA? TIL in our
series, suggesting that this co-inhibitory receptor does not
play a biologically relevant role in breast cancer immu-
nosurveillance. This finding was supported by flow
cytometry analyses of human breast cancers, where less
than 1 % of all cells expressed BTLA, and no BTLA? T
cells were detectable.
In summary, our findings suggest that PD-1 plays a
functional inhibitory role in human breast cancer immu-
nosurveillance, a fact that should encourage immunother-
apeutic approaches targeting the PD-1/PD-L1 signaling
pathway in breast cancer. Further studies investigating the
roles of PD-1 and PD-L1 in breast cancer are
recommended.
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